IL2 and neoplasm: Although we have demonstrated the tumor therapeutic efficacy of VACV strains co-expressing IL2 with tumor-associated antigen epitopes in a mouse model—offering a promising strategy for oncolytic cancer immunotherapy—the translation of this concept into human clinical trials remains challenging.